Intranasal Drug Delivery

Zia, Hossein; Dondeti, Polireddy; Needham, Thomas E.

doi:10.3109/10601339309006446

Cited by 17 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their humidifying effect is opportune and useful, since many allergic and chronic diseases are frequently associated with crusts and drying of mucous membranes. 57 Microbiological stability, irritation and allergic rhinitis are the major drawbacks associated with the water-based dosage forms because the required preservatives diminishes mucociliary function 66 and the reduced chemical stability of the dissolved drug substance and the short residence time of the formulation in the nasal cavity are major drawbacks of liquid formulations. 67,68 The numer-ous variety of dosage forms available in liquid form are described below.…”

Section: Liquid Nasal Formulationsmentioning

confidence: 99%

Targeted Drug Delivery Systems Mediated Through Nasal Delivery for Improved Absorption: an Update

Rakesh¹,

Khan²

2015

RGUHS J Pharm Sci

View full text Add to dashboard Cite

Purpose: This review article focuses on providing updated information about targeting the nasal mucosa for drug delivery. The article would serve as a tool for researchers and students to gain insight into the various aspects of nasal drug delivery. Approach: The anatomy and physiology of the nasal region have been discussed, followed by a discussion of the factors and barriers affecting the drug absorption, strategies to improve the drug absorption, various excipients employed in nasal formulations, different types of nasal formulations and applications of nasal delivery. Findings: The high permeability, high vascularity, very low enzymatic activity, accessible surface area and avoidance of first pass hepatic metabolism are the main factors for which it is being considered as a superior delivery route for many drugs in the recent decades. The effects which are mainly systemic encourage the deployment of this route of administration. This route of drug delivery has been also been exploited for delivering the drugs to the central nervous system bypassing the Blood Brain Barrier (BBB). Different forms of dosage forms such as sprays, powders, gels, solutions are administered through this route. Conclusion: Intranasal delivery of drugs is a promising alternative to other routes of administration because, it is rapid and non-invasive and leads to increased bioavailability of poorly bioavailable drugs. The dose of the drug used is minimal compared to other routes hence the systemic side effects are reduced. Compared to parenteral administration it has better compliance and improved patient acceptability. More fundamental research will lead to better understanding of this route and eventually more marketed products.

show abstract

Section: Liquid Nasal Formulationsmentioning

confidence: 99%

Targeted Drug Delivery Systems Mediated Through Nasal Delivery for Improved Absorption: an Update

Rakesh¹,

Khan²

2015

RGUHS J Pharm Sci

View full text Add to dashboard Cite

show abstract

“…The poor absorption of drugs across the nasal membrane is because of such factors as low permeability of nose membrane to the high molecular weight polymers, mucociliary clearance and so quick removal of drugs, and enzymatic degradation (Zia et al 1993). These limitations can be overcome by 32 J. VARSHOSAZ ET AL.…”

mentioning

confidence: 99%

Nasal Delivery of Insulin Using Bioadhesive Chitosan Gels

2006

View full text Add to dashboard Cite

Recently nasal delivery of insulin has gained considerable attention. Some limitations of this route include rapid mucociliary clearance of the drug from the site of deposition resulting in short time span available for absorption and low permeability of the nasal membrane for peptides. The objective of the present study was development of a chitosan bioadhesive gel for nasal delivery of insulin. A nasal perfusion test was used to study the toxicity of 4 absorption enhancers: saponin, sodium deoxycholate, ethylendiamine tetra-Acetic Acid (EDTA) and lecithin. The gels contained 4,000 Iu/dl insulin, 2 or 4% of low and medium molecular weight of chitosan, and lecithin or EDTA. Drug release was studied by a membraneless diffusion method and bioadhesion by a modified tensiometry test. The optimized gel was administered nasally in diabetic rats. The serum insulin levels were analyzed by an insulin enzyme immunoassay kit and serum glucose by glucose oxidase method kits. Formulations containing 2% of low molecular weight of chitosan with EDTA had higher release percentage and dissolution efficiency (DE)(2.5%), lower T(50%) (Time required to release 50% of the drug), mean dissolution time, and bioadhesion than gels containing 4% of medium molecular weight of chitosan with lecithin. Insulin was released by a zero-order kinetic from the gels. The gel of 2% medium molecular weight of chitosan with EDTA caused increase in insulin absorption and reduction the glucose level by as much as 46% of the intravenous route. Considering our in vitro and in vivo studies, the proposed gel formulation could be a useful preparation for controlled delivery of insulin through the nasal route.

show abstract

“…The intranasal route is an attractive method of drug delivery for antimigraine agents because it is associated with rapid absorption. Intranasal delivery circumvents drug degradation/ metabolism in the gastrointestinal tract or liver as well as delayed absorption due to a gastric stasis common in migraine (Duchene and Ponchel 1993;Zia, Dondeti, and Needham 1993).…”

mentioning

confidence: 99%

Intranasal Toxicity of BMS-181885, A Novel 5-HT1 Agonist

et al. 1999

View full text Add to dashboard Cite

One-month intranasal toxicity studies were conducted with BMS-181885 at doses of 1.5, 9, or 15 mg/animal/day in rats and 4, 24, or 40 mg/animal/day in monkeys. A 1-month intermittent intranasal toxicity study was also conducted in monkeys at doses of 3, 6, and 12 mg/animal 3 days per week. BMS-181885 was generally well tolerated in rats but resulted in dose-dependent nasal mucosal injury, primarily characterized by subacute inflammation of the nasal mucosa, and degeneration, single-cell necrosis, and/or erosion of the olfactory epithelium and, to a lesser extent, the respiratory epithelium. In monkeys, daily BMS-181885 administration was well tolerated and produced similar dose-dependent nasal injury primarily characterized by subacute inflammation of the nasal mucosa with degeneration and erosion of the olfactory epithelium. In a separate experiment, intermittent administration also resulted in dose-dependent nasal injury. In cultured rat nasal mucosal cells, BMS-181885 was toxic to olfactory epithelial cells with a range of mean IC50s between 44 and 291 μM. In contrast, BMS-181885 had no effect on respiratory epithelial cells up to its maximum solubility. Cytochrome P450 inhibition had no effect on the toxicity of BMS-181885 in olfactory epithelial cells but produced dose-dependent toxicity in respiratory epithelial cells, which was not present previously. The in vitro data suggest that parent drug, rather than a toxic metabolite, caused the drug-associated nasal mucosal injury.

show abstract

Intranasal Drug Delivery

Cited by 17 publications

References 60 publications

Targeted Drug Delivery Systems Mediated Through Nasal Delivery for Improved Absorption: an Update

Targeted Drug Delivery Systems Mediated Through Nasal Delivery for Improved Absorption: an Update

Nasal Delivery of Insulin Using Bioadhesive Chitosan Gels

Intranasal Toxicity of BMS-181885, A Novel 5-HT1 Agonist

Contact Info

Product

Resources

About